On a bDMARD with poor response RA, what is the next recommended step?

On a bDMARD with poor response RA, what is the next recommended step?

• A. Add steroids only
• B. Stop therapy
• C. Switch to alt bDMARDs or tsDMARDs
• D. Increase current dose

Answer: (C)

When a patient with rheumatoid arthritis does not respond adequately to a biologic DMARD, the best move is to switch to another agent with a different mechanism, either another bDMARD or a targeted synthetic DMARD. This approach addresses the issue that not all patients respond to the same inflammatory pathway; moving to a different target—such as IL-6, B cells, T-cell co-stimulation, or JAK signaling—offers a better chance of achieving disease control. Why this is preferred: poor response can be due to primary nonresponse or loss of response over time, which can occur from immunogenicity or the pathway simply not driving that patient’s disease. Switching to a different mechanism can overcome that and yield improved outcomes. Simply increasing the dose of the same agent has limited benefit and can raise adverse effects without reliably restoring control. Adding steroids may help with symptoms temporarily, but it doesn’t modify the underlying disease long-term and is not a substitute for changing the ineffective therapy. Stopping therapy abruptly risks a flare and loss of disease control. In practice, clinicians also assess adherence, optimize concomitant methotrexate use if appropriate, and screen for infections and comorbidities before switching to a different biologic or to a tsDMARD.

When a patient with rheumatoid arthritis does not respond adequately to a biologic DMARD, the best move is to switch to another agent with a different mechanism, either another bDMARD or a targeted synthetic DMARD. This approach addresses the issue that not all patients respond to the same inflammatory pathway; moving to a different target—such as IL-6, B cells, T-cell co-stimulation, or JAK signaling—offers a better chance of achieving disease control.

Why this is preferred: poor response can be due to primary nonresponse or loss of response over time, which can occur from immunogenicity or the pathway simply not driving that patient’s disease. Switching to a different mechanism can overcome that and yield improved outcomes. Simply increasing the dose of the same agent has limited benefit and can raise adverse effects without reliably restoring control. Adding steroids may help with symptoms temporarily, but it doesn’t modify the underlying disease long-term and is not a substitute for changing the ineffective therapy. Stopping therapy abruptly risks a flare and loss of disease control.

In practice, clinicians also assess adherence, optimize concomitant methotrexate use if appropriate, and screen for infections and comorbidities before switching to a different biologic or to a tsDMARD.